LoginSubscribe Now
International In-house Counsel Journal Logo
International In-house Counsel Journal Logo
  • Home
  • Business Sectors
  • Areas of Law
  • Editorial Board
  • Write a Paper
  • Subscribe
  • Books
  • Reports
  • Back Issues
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • PLS LogoCopyright & permissions
© 2026 International In-house Counsel Journal Ltd. | ISSN 1754-0607 | Picture Credits: Freepix, Unsplash and by permission of the authors
Back to library search

Pharmaceutical Ethic Codes: How to draft a Pharmaceutical Ethic Codes without inhibiting your business

January 2011Corporate GovernancePharmaceutical

Abstract

Pharmaceutical Industry is very risky business, not only that the company needs to grow its profit but it must show to the people that they contribute to the human health without taking any advantage from the people illness and also making sure that the medicines will not having any bad side effect to the human body. So, for running its business the Pharmaceutical Company should establish Compliance & Ethic Code Program to make sure that the Production Department must maintain the Good Manufacturing Practices and the Sales Department shall always convince the physician to prescribe the products without breaching any medical ethic. But sometimes the Compliance and Ethic Code Program are inhibiting the pharmaceuticals business growth because some of the clauses prohibit some actions while in some areas it is a common business practices. For example, some countries prohibit commercial advertising in television or public newspaper for Ethical Products. In connection with above-mentioned purposes, it’s an In-house legal counsel duty to maintain the Compliance and Ethic Code Program and compromise with the business practices at the same time. It’s our jobs to determine that the corporate actions by employees should be complying with the prevailing laws and regulation. I want to bring up a phrase “To be idealist is good choice but to be compromise it’s a better choice”, it means that in order to survive in the Pharmaceutical Company, in-house legal should be in the position of compromise status. So when we draft a Compliance and Ethic Code, we must make sure that the draft still comply with local regulation and at same times its not eliminate the ability of the Pharmaceutical Company and its employees in competing with its competitors.

Subscribe to reador
PLS Logo Copyright & permissions

Author

Tri Junanto Wicaksono

Head of GA & Legal, PT. Amerta Indah Otsuka, Indonesia

Related Papers

The new EFPIA Disclosure Code – Is the Need for Transparency Outweighing Data Privacy Compliance?
European Federation of Pharmaceutical Industries and Associations (EFPIA) adopted on 24 June 2013, the EFPIA Disclosure Code, that is a code of conduct which obliges its member companies, from 2016,...Read more
Portrait image of John Giannakakis
John Giannakakis
Regional Counsel Southern Europe, G4s Rms, Greece
Conducting Effective Global Anti–Money Laundering Investigations in a Complex Regulatory Environment
Global anti–money laundering (AML) investigations present complex operational and regulatory challenges driven by cross-border transactions, fragmented data sources, varying legal regimes, data protection and privacy requirements, and cultural barriers to...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Kwanza Burney
Kwanza Burney
Compliance & Risk Professional | M.S.L. Candidate (Fordham Law), Fordham University School of Law, USA
“Crisis-Capable Compliance: The CCO at the Crossroads of AI, Ethics, and Leadership”
The role of the Chief Compliance Officer is undergoing a fundamental transformation in the era of artificial intelligence. No longer confined to oversight and enforcement, the CCO is emerging as...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Dolores Guzman
Dolores Guzman
Legal & Compliance Director, Apex America, UK
Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Valentina Lacerca-Allen
Valentina Lacerca-Allen
Title Marketing/ Communication Specialist, Ethiprax LLC., USA